Q3 2025 Performance - Revenue reached $223.1 million, with organic growth of 4.7% compared to Q3 2024[12] - Adjusted EBITDA increased by 14.7% to $52.4 million compared to Q3 2024, with contributions from both segments[15] - Adjusted Free Cash Flow generation was $18 million in Q3 2025, with $53 million YTD and a 35% YTD conversion rate[12] - Adjusted diluted EPS increased by 50% to $0.12[41] Nuclear Power Momentum - Nuclear Power end-market organic revenue grew by 11% YTD[8] - Adjusted Orders in Nuclear Power end-market increased by 21% in Q3 2025 compared to Q3 2024[16] - SMR-related orders amounted to $17 million in Q3 2025, a 9% increase compared to Q3 2024[17] - A $10 million SMR new build order was secured in Q3 2025, and a $55 million installed base order was secured in October 2025[8] Medical Segment Update - Approximately 75% of the Medical segment's revenue is directly related to cancer care[27] - Dosimetry organic revenue grew by 7%[57] 2025 Guidance - The company is on track for 2025 guidance[11] - Organic Revenue Growth is projected between 4.5% and 6.0%, and Total Revenue Growth between 7.0% and 9.0%[62]

Group 1 - The stock price of Oncology Institute has increased by 1,130% through October 16, significantly outperforming major technology stocks like Nvidia and Tesla, which gained 35.4% and 6.2% respectively, while Apple saw a decline of 1.2% [1][8] - Oncology Institute, founded in 2007, offers a variety of cancer care services, including physician care, infusions, radiation, pharmacy services, and clinical trials, aiming to operate under value-based contracts that incentivize cost-effective, high-quality healthcare [4][5] - The company operates in 16 markets across five states and has experienced rapid revenue growth, with a 21.5% increase in second-quarter revenue to $119.8 million, although it reported an operating loss of $11.2 million, which is an improvement from the previous year's loss of $16.4 million [5][6] Group 2 - The future prospects for companies like Oncology Institute that enhance cost-effectiveness and improve outcomes in the U.S. healthcare system are promising, but it remains uncertain when or if the company will achieve profitability [6] - Despite the significant stock price increase, there are recommendations to consider other investment opportunities, as Oncology Institute was not included in a list of the 10 best stocks identified by The Motley Fool Stock Advisor [7][8]